Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data of candidates for prostate cancer active surveillance

ABSTRACT: Expression data of candidates for prostate cancer active surveillance

PROVIDER: PRJNA489796 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

RNAseq of prostate biopsy tissue from prostate cancer patients on active surveillance over 12 months on different diets (ESCAPE trial)

Project description:There is a need to understand genetic and lifestyle factors that may influence the risk of cancer progression in men who have organ-confined prostate cancer and have chosen a programme of 'active surveillance' as opposed to radical treatment with the associated health risks. Epidemiological studies have suggested that consumption of cruciferous vegetables is associated with reduced risk of developing aggressive prostate cancer. In this study we recruited men on active surveillance for low- to intermediate-risk prostate cancer to determine whether a 12-month dietary intervention can elicit transcriptional or nmetabolic responses in their prostate that would be consistent with a reduction in the risk of progression. We undertook RNAseq on prostate biopsies collected before and after a 12-month intervention with broccoli soups.

2020-01-01 | E-MTAB-6525 | biostudies-arrayexpress

Expression data of candidates for prostate cancer active surveillance

Project description:The dataset consists of 266 NCCN very low/low or favorable-intermediate risk PCa patients who underwent diagnostic prostate biopsy between 2000 and 2014 and were treated with RP in six community or academic practices: University of Calgary, Cedars-Sinai, Spectrum Health, Cleveland Clinic, MD Anderson Cancer Center and Johns Hopkins. All patients had complete tumor pathology from biopsy and prostatectomy. Low risk PCa was defined as T1c or cT2a, and Gleason score (GS) ≤ 6, and PSA < 10ng/ml and favorable-intermediate risk was no greater than predominant GS 3 and percent positive biopsy cores < 50%, and either cT2b-cT2c or PSA 10-20ng/ml.

2018-09-08 | GSE119616 | GEO

CIDR: Impact of Genetic Variants on Failure of Active Surveillance for Prostate Cancer

Project description:CIDR: Impact of Genetic Variants on Failure of Active Surveillance for Prostate Cancer

| PRJNA643309 | ENA

CIDR: Impact of Genetic Variants on Failure of Active Surveillance for Prostate Cancer

Project description:CIDR: Impact of Genetic Variants on Failure of Active Surveillance for Prostate Cancer

| PRJNA643310 | ENA

RNAseq of prostate biopsy tissue from prostate cancer patients on active surveillance over 12 months on different diets (ESCAPE trial)

Project description:RNAseq of prostate biopsy tissue from prostate cancer patients on active surveillance over 12 months on different diets (ESCAPE trial)

| PRJEB25542 | ENA

Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance?

Project description: Not available

| S-EPMC3689450 | biostudies-literature

Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance.

Project description: Not available

| S-EPMC8127807 | biostudies-literature

Association of prostate cancer risk alleles with unfavourable pathological characteristics in potential candidates for active surveillance.

Project description: Not available

| S-EPMC4226267 | biostudies-literature

Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance.

Project description: Not available

| S-EPMC6760567 | biostudies-literature

Metabolomic profiling of baseline plasmas from a longitudinal prospective cohort of 491 active surveillance (AS) participants

Project description:Untargeted metabolomics analyses were performed on clinically matched baseline plasma samples (n = 16 per group) prospectively collected from patients with clinically low-risk early stage prostate cancer undergoing AS who exhibited early disease progression (DP) (defined as upgrading of Gleason score (GS) and/or increased tumor volume on surveillance biopsy within 18 months after start of AS) or indolent disease (no progression for five or more years after start of AS) as well as 459 baseline plasma samples prospectively collected from patients with early-stage prostate cancer undergoing AS.

2020-05-19 | ST001408 | MetabolomicsWorkbench

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data